Site Search

Search market news

Find public news by keyword, exact ticker, category and date.

News Feed

1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.

News 2026-10-26 11:35 UTC

Immatics IMA402 shows 32% confirmed response rate in Phase 1b melanoma trial

Immatics reported a 32% confirmed response rate among high-PRAME melanoma patients in its Phase 1b trial of IMA402.